HZNP Horizon Therapeutics Public Limited Company Stock Quote

HZNP [NASD]

Horizon Therapeutics Public Limited Company

Healthcare | Drug Manufacturers - General | Ireland

Index	-	P/E	81.34	EPS (ttm)	1.15	Insider Own	0.80%	Shs Outstand	223.92M	Perf Week	8.75%
Market Cap	20.07B	Forward P/E	18.34	EPS next Y	5.11	Insider Trans	-33.30%	Shs Float	218.68M	Perf Month	0.56%
Income	280.00M	PEG	5.81	EPS next Q	0.88	Inst Own	92.00%	Short Float	2.76%	Perf Quarter	7.85%
Sales	2.19B	P/S	9.18	EPS this Y	-37.60%	Inst Trans	1.65%	Short Ratio	3.52	Perf Half Y	27.40%
Book/sh	17.21	P/B	5.45	EPS next Y	41.31%	ROA	4.60%	Target Price	114.64	Perf Year	99.26%
Cash/sh	3.79	P/C	24.73	EPS next 5Y	14.00%	ROE	8.00%	52W Range	45.01 - 97.20	Perf YTD	28.22%
Dividend	-	P/FCF	36.81	EPS past 5Y	48.20%	ROI	8.90%	52W High	-3.12%	Beta	1.12
Dividend %	-	Quick Ratio	2.10	Sales past 5Y	23.80%	Gross Margin	75.50%	52W Low	109.22%	ATR	3.28
Employees	1640	Current Ratio	2.40	Sales Q/Q	-3.80%	Oper. Margin	14.40%	RSI (14)	58.71	Volatility	3.57% 3.48%
Optionable	Yes	Debt/Eq	0.67	EPS Q/Q	-670.40%	Profit Margin	12.80%	Rel Volume	0.83	Prev Close	93.79
Shortable	Yes	LT Debt/Eq	0.66	Earnings	May 05 BMO	Payout	0.00%	Avg Volume	1.71M	Price	94.17
Recom	1.60	SMA20	2.75%	SMA50	4.49%	SMA200	17.60%	Volume	575,226	Change	0.41%

Mar-22-21

Resumed

Morgan Stanley

Overweight

$103

Mar-12-21

Initiated

Wolfe Research

Outperform

$107

Sep-09-20

Initiated

JP Morgan

Overweight

$110

Aug-27-20

Initiated

Citigroup

Buy

$112

Jan-08-20

Initiated

Goldman

Neutral

$35

Sep-26-19

Initiated

BofA/Merrill

Buy

$34

Sep-12-19

Initiated

Guggenheim

Buy

Aug-14-19

Upgrade

BMO Capital Markets

Market Perform → Outperform

$29 → $36

May-01-19

Upgrade

Citigroup

Neutral → Buy

$21 → $32

Mar-08-19

Upgrade

Morgan Stanley

Equal-Weight → Overweight

$32

Nov-15-18

Downgrade

Mizuho

Buy → Neutral

Jun-27-18

Downgrade

Citigroup

Buy → Neutral

Jan-12-18

Upgrade

Mizuho

Neutral → Buy

$12 → $18

Sep-28-17

Initiated

Goldman

Buy

$16

Jun-16-17

Initiated

Cantor Fitzgerald

Overweight

$13

May-09-17

Reiterated

Stifel

Buy

$35 → $20

May-09-17

Downgrade

Mizuho

Buy → Neutral

$22 → $10

Feb-28-17

Reiterated

Mizuho

Buy

$25 → $22

Dec-16-16

Upgrade

Mizuho

Neutral → Buy

$14 → $25

Dec-09-16

Downgrade

Mizuho

Buy → Neutral

$30 → $14

May-13-21 11:30AM	Horizon Therapeutics plc Ranked #1 in Overall Corporate Reputation Among U.S. Patient Groups that Report Working with the Company Business Wire
May-06-21 04:30PM	Horizon Therapeutics plc to Present at the Bank of America Securities 2021 Health Care Conference Business Wire
08:30AM	New Analysis of UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in Neurology Neuroimmunology & Neuroinflammation Business Wire
08:00AM	Horizon Therapeutics plc Announces Elizabeth H.Z. Thompson as a Healthcare Businesswomens Association 2021 Luminary Business Wire
May-05-21 12:53PM	Is Horizon Therapeutics Public Limited Company (HZNP) A Smart Long-Term Buy? Insider Monkey
07:00AM	Horizon Therapeutics plc Reports First-Quarter 2021 Financial Results; Updating Full-Year 2021 Net Sales Guidance and Full-Year Adjusted EBITDA Guidance to Incorporate Recently Acquired Viela Bio, Inc. Business Wire
May-04-21 01:59PM	Was The Smart Money Right About Horizon Therapeutics (HZNP)? Insider Monkey
Apr-27-21 08:00AM	Horizon Therapeutics plc Ranks Among the Top Companies in Overall Corporate Reputation in 2020 PatientView Survey of Patient Organizations Worldwide Business Wire
Apr-24-21 04:44AM	We Take A Look At Why Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) CEO Has Earned Their Pay Packet Simply Wall St.
Apr-22-21 04:49PM	Top Healthcare Stocks for May 2021 Investopedia
Apr-21-21 07:30AM	HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout PR Newswire
Apr-17-21 06:33AM	3 Reasons to Buy Horizon Therapeutics Stock and 1 Not To Motley Fool
Apr-16-21 08:30AM	New Long-Term Data for UPLIZNA® (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD) Business Wire
08:00AM	New Integrated Data and Follow-up Outcomes From Two TEPEZZA® (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & Endocrinology Business Wire
Apr-12-21 03:58PM	Biotech Stock On Earnings Win Streak Sets Up Bullish Chart Investor's Business Daily
08:30AM	Horizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For® Business Wire
Apr-08-21 08:00AM	Horizon Therapeutics plc to Release First-Quarter 2021 Financial Results and Host Webcast on May 5, 2021 Business Wire
Apr-07-21 08:00AM	RECIPE Randomized Controlled Trial Data Published in Arthritis & Rheumatology Show Higher Response Rates Using KRYSTEXXA® (pegloticase injection) with the Immunomodulator Mycophenolate Mofetil Business Wire
Apr-05-21 08:30AM	New UPLIZNA® (inebilizumab-cdon) Data in People With Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the American Academy of Neurologys 73rd Annual Meeting Business Wire
Mar-30-21 07:30AM	Horizon Therapeutics plc to Resupply Market With TEPEZZA® (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED) Beginning in April Business Wire +8.67%
Mar-29-21 10:05AM	Horizon Therapeutics and Chicago Cubs Announce Legacy Partnership Business Wire
Mar-25-21 01:26PM	Is Horizon Therapeutics (HZNP) A Good Stock to Short? Insider Monkey
08:00AM	First Patient Enrolls in FORWARD Trial to Evaluate Monthly Dosing of KRYSTEXXA® (pegloticase injection) and Methotrexate to Treat Uncontrolled Gout Business Wire
Mar-24-21 08:15AM	UPLIZNA® (inebilizumab-cdon) Approved by Japanese Ministry of Health, Labour and Welfare for the Prevention of Relapses of Neuromyelitis Optica Spectrum Disorder (NMOSD) Business Wire
08:00AM	Horizon Therapeutics plc Launches The Horizon Prize with Massachusetts Institute of Technology (MIT) Solve to Advance Solutions for the Rare Disease Community Business Wire
Mar-23-21 11:18AM	Is HZNP Stock A Buy or Sell? Insider Monkey
Mar-22-21 04:23AM	Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) Stock Is Going Strong: Have Financials A Role To Play? Simply Wall St.
Mar-17-21 01:10PM	Halozyme Stock Joins The 80-Plus RS Rating Club Investor's Business Daily
Mar-16-21 07:35AM	AstraZeneca to supply U.S. with extra 500,000 doses of COVID-19 antibody-based cocktail MarketWatch
Mar-15-21 03:37PM	Few Top Global Growth Stocks To Buy And Watch On IBD's Screen Of The Day Investor's Business Daily
01:05PM	Stocks Showing Leadership: Covid Recovery Play Ligand Earns Key Rating Jump Investor's Business Daily
08:50AM	Horizon Therapeutics plc Completes Acquisition of Viela Bio, Inc. Business Wire
Mar-12-21 08:45AM	Horizon Therapeutics plc Named Number One Best Workplace in Biopharma Business Wire
Mar-11-21 04:51PM	Screen Of The Day: These Growth Stocks Make Bullish Moves Amid Soaring Profits Investor's Business Daily
03:00AM	Horizon Therapeutics plc Named as One of the Best Workplaces in Ireland Business Wire
Mar-10-21 01:36PM	Ligand Pharmaceuticals Gets A Composite Rating Upgrade Investor's Business Daily
Mar-09-21 01:16PM	Biotech stocks are a buy especially these 18 picks MarketWatch
09:40AM	Altimmune Joins Rank Of Stocks With RS Ratings Over 90 Investor's Business Daily
Mar-08-21 09:53AM	Horizon Therapeutics Pivots Towards Explosive Earnings Growth TipRanks
Feb-26-21 04:05PM	Horizon Therapeutics plc to Present at the Cowen and Company 41st Annual Health Care Conference Business Wire
Feb-25-21 04:05PM	Horizon Therapeutics plc Shines a Light on Rare Disease with the Launch of the #RAREis Photobooth to Benefit Make-A-Wish® Business Wire -5.14%
03:27PM	Horizon Therapeutics USA, Inc. -- Moody's: Horizon's term loan upsizing modestly credit negative Moody's
12:03PM	Top-Rated Stocks: Supernus Pharmaceuticals Sees Composite Rating Climb To 96 Investor's Business Daily
Feb-24-21 04:41PM	Horizon Posts Triple-Digit Sales Growth After Adding Tepezza To Lineup Investor's Business Daily +13.29%
11:01AM	Top-Ranked Horizon Therapeutics Hits Key RS Rating Benchmark Investor's Business Daily
07:00AM	Horizon Therapeutics plc Reports Record Fourth-Quarter and Full-Year 2020 Financial Results; Announces Full-Year 2021 Guidance Business Wire
Feb-22-21 09:30AM	New Survey Assessment Finds Debilitating Impact of Thyroid Eye Disease (TED) on Quality of Life Continues Well Beyond Acute Disease into Chronic Phase Business Wire -5.75%
Feb-20-21 08:33PM	(VIE Alert) Johnson Fistel Investigates Proposed Sale of Viela Bio; Are Shareholders Getting a Fair Deal? PR Newswire
Feb-18-21 01:08PM	Inovio Pharmaceuticals Shows Market Leadership With Jump To 86 RS Rating Investor's Business Daily
Feb-17-21 12:44PM	Co-Diagnostics Clears Technical Benchmark, Hitting 90-Plus RS Rating Investor's Business Daily
Feb-10-21 01:40PM	Heat Biologics Stock Notches Scorching RS Rating Investor's Business Daily
Feb-04-21 01:54PM	Anavex Life Sciences Crp Earns 94 RS Rating; Soars To Record High Investor's Business Daily
Feb-03-21 12:53PM	Horizon Pharma Shows Rising Price Performance With Jump To 85 RS Rating Investor's Business Daily
08:00AM	Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2020 Financial Results and Host Webcast on Feb. 24, 2021 Business Wire
Feb-02-21 07:40AM	Horizon To Snap Up Viela Bio For $3B; Shares Climb SmarterAnalyst +9.67%
Feb-01-21 03:12PM	SHAREHOLDER ALERT: WeissLaw LLP Investigates Viela Bio, Inc. PR Newswire +6.29%
02:57PM	Horizon Pharma Sees Rising Composite Rating To 96 Investor's Business Daily
02:05PM	VIELA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of VIE and Encourages Investors to Contact the Firm GlobeNewswire
09:36AM	(VIE Alert) Johnson Fistel Investigates Proposed Sale of Viela Bio; Are Shareholders Getting a Fair Deal? PR Newswire
07:27AM	UPDATE: Horizon Therapeutics to acquire Viela Bio in deal with equity value of $3.05 billion MarketWatch
07:00AM	Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio Business Wire
Jan-26-21 03:39PM	Composite Rating For Pacira Pharmaceuticals Rises To 97 Investor's Business Daily
01:42PM	Dow Jones, S&P 500 Up Slightly After Giving Up Gains; Microsoft In Buy Zones Ahead Of Earnings Investor's Business Daily
Jan-20-21 12:45PM	Top-Rated Stocks: Ligand Pharmaceuticals Sees Composite Rating Climb To 97 Investor's Business Daily
Jan-18-21 08:46PM	Billionaire John Paulsons Top 10 Stock Picks Insider Monkey
Jan-11-21 07:00AM	Horizon Therapeutics plc Provides Preliminary 2020 Financial Results, Exceeding Full-Year 2020 Net Sales and Adjusted EBITDA Guidance; Provides Update on TEPEZZA® (teprotumumab-trbw) Supply and New KRYSTEXXA® (pegloticase injection) Trials Business Wire
Jan-08-21 02:23AM	The Horizon Therapeutics (NASDAQ:HZNP) Share Price Has Soared 428%, Delighting Many Shareholders Simply Wall St.
Jan-05-21 06:00AM	Get Ready for Health-Care Stocks to Go Wild. How to Play Them. Barrons.com
Dec-22-20 08:00AM	Horizon Therapeutics plc to Present at the 39th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-17-20 06:40AM	Horizon Therapeutics plc Announces Short-Term TEPEZZA® (teprotumumab-trbw) Supply Disruption Due to Government-Mandated (Operation Warp Speed) COVID-19 Vaccine Production Business Wire -9.62%
Dec-15-20 04:13PM	United Therapeutics Meets 80-Plus RS Rating Benchmark; Hits New High Investor's Business Daily
10:40AM	Sangamo Therapeutics Sees RS Rating Rise To 85 And Composite Rating At 81 Investor's Business Daily
Dec-14-20 01:58PM	Intra-Cellular Therapies Getting Closer To Key Technical Benchmark Investor's Business Daily
Dec-09-20 10:42AM	Sarepta Therapeutics Sees Relative Strength Rating Improve To 74 Investor's Business Daily
Dec-07-20 01:57PM	Sarepta Therapeutics Earns Relative Strength Rating Upgrade Investor's Business Daily
01:11PM	Is HZNP A Good Stock To Buy Now? Insider Monkey
10:56AM	Top Pharmaceutical Stocks for Q1 2021 Investopedia
Dec-03-20 09:00AM	Horizon Therapeutics plc Provides $1 Million in Scholarships to Help Economically Disadvantaged Students and Students of Color Further Their Liberal Arts and Health Professions Education Business Wire
Dec-02-20 09:15AM	Great Place to Work Names Horizon Therapeutics plc to Best Workplaces for Parents List Business Wire
Dec-01-20 02:22AM	How Much Did Horizon Therapeutics' (NASDAQ:HZNP) CEO Pocket Last Year? Simply Wall St.
Nov-30-20 08:00AM	Horizon Therapeutics plc Donates Additional $1.2 Million to Support COVID-19 Relief Efforts in Illinois and Other Impacted U.S. and International Communities Business Wire
Nov-25-20 08:00AM	Horizon Therapeutics plc to Participate in Upcoming Investor Conferences Business Wire
Nov-23-20 08:00AM	Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology PR Newswire
08:00AM	Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology Business Wire
Nov-18-20 10:11AM	Investing Strategies: Horizon Therapeutics CEO, Chegg CFO, O'Neil Investment Strategist Share Insights Investor's Business Daily
Nov-17-20 09:15AM	National Association for Business Resources Names Horizon Therapeutics One of the Best and Brightest Companies to Work For in the Nation Business Wire
Nov-16-20 10:54AM	First Thyroid Eye Disease (TED) Awareness Week to Increase Education and Understanding of Vision-Threatening Disease Business Wire
Nov-13-20 10:40AM	Pacira Pharmaceuticals Meets 80-Plus Relative Strength Rating Benchmark Investor's Business Daily
10:31AM	Atara Biotherapeutics Moves With Rising Relative Price Strength Investor's Business Daily
08:30AM	New Data Build on Growing Evidence Supporting TEPEZZA® (teprotumumab-trbw) Efficacy in Thyroid Eye Disease (TED), Including in Patients With Less Severe Disease and Longer Disease Duration Business Wire
08:00AM	Horizon Therapeutics plc CEO Tim Walbert Honored with RARE Champion Award at Global Genes Champions of Hope Gala Business Wire
Nov-12-20 08:00AM	Horizon Therapeutics plc to Participate in Upcoming Investor Conferences Business Wire
Nov-03-20 12:50AM	Horizon Therapeutics CEO On Success Of Key Drug Tepezza, Acquisition Plans Investor's Business Daily Video
Nov-02-20 04:15PM	Horizon Therapeutics Easily Tops Views, Hikes Outlook, But HZNP Stock Falls Investor's Business Daily
02:00PM	Higher Response Rates in RECIPE Randomized Controlled Trial of KRYSTEXXA® (pegloticase injection) Concomitantly Used with the Immunomodulator Mycophenolate Mofetil Business Wire
08:12AM	Horizon Therapeutics: Q3 Earnings Insights Benzinga
07:00AM	Horizon Therapeutics plc Reports Record Third-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $800 Million; Increases Full-Year 2020 Net Sales and Adjusted EBITDA Guidance Business Wire
06:58AM	Horizon Therapeutics plc Names Karin Rosén, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer Business Wire
Oct-30-20 09:15AM	Chicago Tribune Names Horizon Therapeutics a 2020 Top Workplace for the Sixth Consecutive Year Business Wire
08:00AM	New TEPEZZA® (teprotumumab-trbw) Data to Be Presented at the American Academy of Ophthalmology 2020 Annual Meeting Business Wire

Horizon Therapeutics Public Limited Company focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. It operates in two segments, Orphan and Inflammation. Its medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare lysosomal storage disorder; ACTIMMUNE for chronic granulomatous disease and severe malignant osteopetrosis; RAYOS for the treatment of rheumatoid arthritis (RA), ankylosing spondylitis (AS), polymyalgia rheumatica, primary systemic amyloidosis, asthma, chronic obstructive pulmonary disease, systemic lupus erythematosus, and other conditions; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company also offers PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis (OA) of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; and VIMOVO for the relief of signs and symptoms of OA, RA, and AS to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hoelscher Paul W.	EVP, CFO	May 14	Sale	90.01	102,925	9,263,847	172,226	May 14 06:12 PM
Kent Jeff	See remarks	May 11	Option Exercise	22.14	12,592	278,787	83,586	May 12 05:02 PM
Daniel William F	Director	May 10	Option Exercise	12.70	20,000	254,000	20,000	May 12 05:01 PM
Daniel William F	Director	May 10	Sale	86.56	20,000	1,731,275	0	May 12 05:01 PM
Walbert Timothy P	Chairman, President and CEO	Apr 30	Sale	94.98	25,000	2,374,413	899,838	Apr 30 07:03 PM
GREY MICHAEL G	Director	Apr 12	Option Exercise	2.37	15,000	35,550	15,000	Apr 13 06:03 PM
MOZE BARRY	EVP, Chief Admin. Officer	Apr 12	Sale	88.96	65,613	5,837,049	105,665	Apr 13 06:04 PM
GREY MICHAEL G	Director	Apr 12	Sale	90.28	15,000	1,354,200	0	Apr 13 06:03 PM
Camardo Daniel A.	EVP and President, U.S.	Apr 05	Option Exercise	24.18	18,281	442,093	51,181	Apr 05 05:25 PM
CURTIS GEOFFREY M.	EVP, Corporate Affairs, CCO	Apr 01	Option Exercise	28.40	37,000	1,050,710	123,414	Apr 02 05:13 PM
CURTIS GEOFFREY M.	EVP, Corporate Affairs, CCO	Apr 01	Sale	93.51	70,739	6,615,094	52,675	Apr 02 05:13 PM
Beeler Brian K	EVP, General Counsel	Mar 31	Sale	90.12	26,844	2,419,181	95,677	Apr 02 05:11 PM
Camardo Daniel A.	EVP and President, U.S.	Mar 30	Sale	85.50	12,900	1,103,006	32,900	Mar 31 05:11 PM
Shannon James Samuel	Director	Mar 01	Option Exercise	12.19	7,232	88,158	7,232	Mar 03 04:46 PM
Shannon James Samuel	Director	Mar 01	Sale	91.30	7,232	660,261	0	Mar 03 04:46 PM
Walbert Timothy P	Chairman, President and CEO	Mar 01	Sale	91.35	26,975	2,464,137	924,838	Mar 03 04:44 PM
SANTINI GINO	Director	Mar 01	Sale	91.47	12,000	1,097,600	23,795	Mar 03 04:45 PM
DesJardin Michael A.	EVP, Technical Operations	Feb 26	Sale	91.83	1,099	100,921	86,247	Feb 26 06:12 PM
DesJardin Michael A.	EVP, Technical Operations	Feb 24	Sale	92.48	15,944	1,474,448	87,346	Feb 26 06:12 PM
Konstantinovsky Irina	EVP, Chief Human Resources Off	Feb 22	Sale	87.22	5,698	496,987	81,677	Feb 23 06:19 PM
Karnani Vikram	EVP & President, International	Feb 22	Sale	87.19	8,358	728,722	104,165	Feb 23 06:20 PM
DesJardin Michael A.	EVP, Technical Operations	Feb 11	Sale	90.00	10,786	970,740	101,200	Feb 12 05:01 PM
DesJardin Michael A.	EVP, Technical Operations	Feb 02	Sale	85.00	4,530	385,050	111,986	Feb 04 05:39 PM
Walbert Timothy P	Chairman, President and CEO	Feb 01	Option Exercise	0.00	9,087	0	22,895	Feb 03 05:24 PM
Karnani Vikram	EVP & President, International	Jan 22	Sale	76.81	2,731	209,768	111,429	Jan 22 09:05 PM
Walbert Timothy P	Chairman, President and CEO	Jan 22	Sale	76.47	11,323	865,917	946,559	Jan 22 08:59 PM
Konstantinovsky Irina	EVP, Chief Human Resources Off	Jan 22	Sale	76.81	2,226	170,979	86,500	Jan 22 09:04 PM
Konstantinovsky Irina	EVP, Chief Human Resources Off	Jan 21	Option Exercise	0.00	3,999	0	90,498	Jan 22 09:04 PM
MOZE BARRY	EVP, Chief Admin. Officer	Jan 21	Option Exercise	0.00	5,819	0	172,762	Jan 22 09:03 PM
Kent Jeff	See remarks	Jan 21	Option Exercise	0.00	3,045	0	71,468	Jan 22 09:02 PM
Hoelscher Paul W.	EVP, CFO	Jan 21	Option Exercise	0.00	5,556	0	6,605	Jan 22 09:01 PM
Walbert Timothy P	Chairman, President and CEO	Jan 21	Option Exercise	0.00	2,575	0	14,563	Jan 22 08:59 PM
Walbert Timothy P	Chairman, President and CEO	Jan 21	Option Exercise	0.00	20,330	0	966,889	Jan 22 08:59 PM
SHERMAN JEFFREY W	EVP and Chief Medical Officer	Jan 21	Option Exercise	0.00	5,353	0	81,361	Jan 22 09:00 PM
Camardo Daniel A.	EVP and President, U.S.	Jan 21	Option Exercise	0.00	3,220	0	46,503	Jan 22 09:09 PM
Beeler Brian K	EVP, General Counsel	Jan 21	Option Exercise	0.00	4,120	0	123,472	Jan 22 09:08 PM
McHugh Miles W	Sr VP & Princ. Acctg Officer	Jan 21	Option Exercise	0.00	3,590	0	35,206	Jan 22 09:08 PM
DesJardin Michael A.	EVP, Technical Operations	Jan 21	Option Exercise	0.00	3,678	0	118,340	Jan 22 09:06 PM
CURTIS GEOFFREY M.	EVP, Corporate Affairs, CCO	Jan 21	Option Exercise	0.00	3,760	0	87,205	Jan 22 09:07 PM
Karnani Vikram	EVP & President, International	Jan 21	Option Exercise	0.00	4,904	0	116,333	Jan 22 09:05 PM
Walbert Timothy P	Chairman, President and CEO	Jan 15	Sale	77.89	211,204	16,449,893	946,559	Jan 15 05:43 PM
DesJardin Michael A.	EVP, Technical Operations	Jan 06	Option Exercise	16.35	27,106	443,296	141,768	Jan 08 05:32 PM
Konstantinovsky Irina	EVP, Chief Human Resources Off	Jan 06	Sale	74.76	26,844	2,006,854	86,499	Jan 08 05:33 PM
Karnani Vikram	EVP & President, International	Jan 06	Sale	75.00	30,031	2,252,325	111,429	Jan 08 05:31 PM
DesJardin Michael A.	EVP, Technical Operations	Jan 06	Sale	75.00	27,106	2,032,950	114,662	Jan 08 05:32 PM
McHugh Miles W	Sr VP & Princ. Acctg Officer	Dec 14	Sale	80.00	1,856	148,480	19,741	Dec 15 05:00 PM
DesJardin Michael A.	EVP, Technical Operations	Dec 10	Sale	69.64	5,909	411,503	63,392	Dec 11 04:41 PM
SHERMAN JEFFREY W	EVP and Chief Medical Officer	Dec 08	Sale	71.15	40,764	2,900,354	174,955	Dec 09 05:05 PM
SHERMAN JEFFREY W	EVP and Chief Medical Officer	Dec 07	Sale	70.94	63,078	4,474,860	215,719	Dec 09 05:05 PM
McHugh Miles W	Sr VP & Princ. Acctg Officer	Nov 12	Sale	75.48	12,124	915,120	21,597	Nov 13 07:27 PM
Camardo Daniel A.	EVP and President, U.S.	Nov 06	Sale	76.76	3,500	268,663	30,829	Nov 06 06:00 PM
Kent Jeff	See remarks	Nov 05	Sale	78.94	47,944	3,784,663	51,049	Nov 06 06:00 PM
MOZE BARRY	EVP, Chief Admin. Officer	Nov 05	Sale	78.93	77,500	6,117,259	100,709	Nov 06 06:00 PM
SHERMAN JEFFREY W	EVP and Chief Medical Officer	Oct 21	Option Exercise	7.61	13,000	98,930	28,015	Oct 21 05:06 PM
Konstantinovsky Irina	EVP, Chief Human Resources Off	Sep 17	Option Exercise	14.05	21,351	299,982	57,373	Sep 18 05:00 PM
Konstantinovsky Irina	EVP, Chief Human Resources Off	Sep 16	Sale	78.88	8,919	703,531	36,022	Sep 18 05:00 PM
Beeler Brian K	EVP, General Counsel	Sep 04	Option Exercise	14.91	28,143	419,666	64,028	Sep 08 04:51 PM
Hoelscher Paul W.	EVP, CFO	Aug 24	Sale	75.76	29,576	2,240,702	102,925	Aug 25 05:16 PM
Walbert Timothy P	Chairman, President and CEO	Aug 06	Sale	72.54	110,000	7,979,414	733,792	Aug 07 05:42 PM
GREY MICHAEL G	Director	Aug 05	Option Exercise	3.95	1,755	6,932	1,755	Aug 07 05:40 PM
GREY MICHAEL G	Director	Aug 05	Sale	73.35	1,755	128,729	0	Aug 07 05:40 PM
Karnani Vikram	EVP & President, International	Aug 03	Option Exercise	13.15	36,772	483,636	78,941	Aug 05 01:24 PM
SANTINI GINO	Director	Aug 03	Option Exercise	2.88	35,795	103,262	35,795	Aug 04 04:56 PM
GREY MICHAEL G	Director	Jul 22	Option Exercise	3.95	1,755	6,932	1,755	Jul 22 05:33 PM
GREY MICHAEL G	Director	Jul 22	Sale	60.00	1,755	105,300	0	Jul 22 05:33 PM
Kent Jeff	See remarks	Jul 07	Option Exercise	5.68	38,000	215,980	98,993	Jul 07 06:57 PM
MOZE BARRY	EVP, Chief Admin. Officer	Jul 07	Option Exercise	13.17	35,076	461,918	178,209	Jul 07 06:50 PM
SHERMAN JEFFREY W	EVP and Chief Medical Officer	Jul 06	Sale	57.50	9,100	523,250	278,797	Jul 07 06:49 PM
MOZE BARRY	EVP, Chief Admin. Officer	Jul 01	Sale	54.64	23,158	1,265,441	143,133	Jul 02 04:46 PM
GREY MICHAEL G	Director	Jun 25	Option Exercise	3.95	1,755	6,932	1,755	Jun 26 05:00 PM
GREY MICHAEL G	Director	Jun 25	Sale	55.00	1,755	96,525	0	Jun 26 05:00 PM
Kent Jeff	See remarks	Jun 10	Sale	48.05	2,785	133,819	60,993	Jun 12 06:00 PM
Kent Jeff	See remarks	Jun 01	Sale	49.94	57,215	2,857,179	60,994	Jun 02 06:18 PM
Karnani Vikram	EVP, Chief Commercial Officer	Jun 01	Sale	50.23	2,369	118,995	42,169	Jun 02 06:17 PM
Beeler Brian K	EVP, General Counsel	Jun 01	Sale	50.23	2,370	119,045	35,885	Jun 02 06:16 PM
CURTIS GEOFFREY M.	EVP, Corporate Affairs, CCO	May 26	Sale	49.85	21,918	1,092,612	34,834	May 27 05:00 PM
GREY MICHAEL G	Director	May 22	Option Exercise	7.84	10,530	82,555	10,530	May 26 05:00 PM
GREY MICHAEL G	Director	May 22	Sale	48.77	10,530	513,505	0	May 26 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience